联合凝血功能指标在结直肠癌患者化疗后高凝状态监测中的应用价值

陆悦, 卢仁泉, 张杰, 郑慧

  1. 复旦大学附属肿瘤医院检验科,复旦大学上海医学院肿瘤学系,上海 200032
  • 收稿日期:2023-11-05 修回日期:2024-02-13 出版日期:2024-03-30 发布日期:2024-04-08
  • 通信作者: 郑慧
  • 作者简介:陆悦(ORCID: 0009-0003-8813-1776),本科,技师。

摘要/Abstract

摘要:

背景与目的:常规凝血实验(conventional coagulation test,CCT)检测所用的血浆仅能够反映某个凝血时间点/段的单一成分,而血栓弹力图(thromboelastography,TEG)检测能够描绘凝血及纤维蛋白溶解的整体动态过程的曲线,更能独立完整地反映血液的真实状态,可作为凝血功能检测的补充。本研究旨在评估联合凝血功能指标在结直肠癌患者化疗后高凝状态监测中的应用价值,探讨结直肠癌患者化疗后血栓形成的危险因素,为临床监测高凝状态提供参考。方法:选取复旦大学附属肿瘤医院2021年6月—2023年6月收治的160例结直肠癌患者作为实验组,并选取同期的80名健康体检者作为对照组,再将实验组以是否合并血栓分为未合并血栓组(82例)和合并血栓组(78例)。研究3组对象的TEG[包括凝血反应时间(coagulation reaction time,R)、凝血形成时间(coagulation formation time,K)、血细胞凝块形成速率(blood clot formation rate,Angle)、血栓最大振幅(maximum amplitude,MA)和凝血综合指数(coagulation index,CI)]、CCT[包括活化部分凝血活酶时间(activated partial thromboplastin time,APTT)、凝血酶原时间(prothrombin time,PT)、凝血酶时间(thrombin time,TT)、纤维蛋白原(fibrinogen,Fib)、D-二聚体(D-dimer,DD)和纤维蛋白原降解产物(fibrinogen degradation products,FDP)]及血小板计数(platelet count,PLT)的差异。以是否合并血栓作为高凝状态的标准,选择其中差异有统计学意义的指标纳入二元logistic回归分析,并绘制受试者工作特征(receiver operating characteristic,ROC)曲线,分析单独及联合检测凝血功能指标对结直肠癌患者化疗后高凝状态的诊断效能。收集160例结直肠癌患者的基础信息、肿瘤分期和深静脉血栓Autar评估量表,进行logistic回归分析,探索血栓形成的危险因素。本研究经复旦大学附属肿瘤医院伦理委员会审核通过(编号:050432-4-2108*)。结果:与对照组相比,未合并血栓组的R、TT和PLT均减小(P<0.05),APTT、PT、DD和FDP均增大(P<0.05);合并血栓组与对照组的各项指标差异均有统计学意义(P<0.05)。与未合并血栓组相比,合并血栓组的K减小(P<0.05),Angle、MA、CI、Fib、DD和FDP均增大(P<0.05)。ROC曲线分析显示,在结直肠癌患者化疗后高凝状态评估中,TEG检测的曲线下面积(area under curve,AUC)为0.756,灵敏度为67.5%,特异度为73.8%;CCT检测的AUC为0.691,灵敏度为78.8%,特异度为56.2%;联合检测的AUC为0.840,灵敏度为80.0%,特异度为77.5%。在危险因素分析中,肿瘤分期、远处转移和Autar评分与结直肠癌患者化疗后血栓的形成相关(P<0.05),3个危险因素在K、Angle、MA、CI、Fib、DD和FDP中的差异也有统计学意义(P <0.05)。结论:K、Angle、MA、CI、Fib、DD和FDP是反映高凝状态的主要指标,TEG与CCT联合检测能更好地反映结直肠癌患者化疗后的凝血状态。肿瘤分期为Ⅲ ~ Ⅳ期、有远处转移和Autar评分高可能是血栓形成的危险因素,提示可通过监测高危人群的相关凝血指标以降低血栓的发生率。

关键词: 结直肠癌, 化疗, 血栓弹力图, 常规凝血实验, 血栓

Abstract:

Background and purpose: The plasma used for routine coagulation test (CCT) can only reflect a single component at a certain coagulation time point/segment, while thromboelastography (TEG) can depict the overall dynamic process curve of coagulation and fibrinolysis, which can more independently and completely reflect the true state of the blood and can serve as a supplement to coagulation function testing. This study aimed to evaluate the application value of combined coagulation function indexes in monitoring the hypercoagulable state of patients with colorectal cancer after chemotherapy, and to explore the risk factors of thrombosis in patients with colorectal cancer after chemotherapy, so as to provide reference for clinical monitoring of hypercoagulable state. Methods: A total of 160 patients with colorectal cancer from Fudan University Shanghai Cancer Center from June 2021 to June 2023 were selected as the experimental group, and 80 healthy subjects were selected as the control group. Then the experimental group was divided into a group without thrombosis (82 cases) and a group with thrombosis (78 cases) according to whether they had thrombosis or not. The determinations of thromboelastography (TEG) [coagulation reaction time (R), coagulation formation time (K), blood clot formation rate (α-Angle), maximum amplitude (MA) and coagulation index (CI)], conventional coagulation tests (CCT) [activated partial thromboplastin time (APTT), prothrombin time (PT), thrombin time (TT), fibrinogen (Fib), D-dimer (DD), fibrinogen degradation products (FDP)] and platelet count (PLT) were studied among three groups. With or without thrombosis as the criterion of hypercoagulable state, statistically significant indicators were selected to be included in the binary logistic regression analysis, and the receiver operating characteristic (ROC) curve was drawn to analyze the diagnostic efficacy of single and combined detection of the coagulation function indicators for hypercoagulable state in patients with colorectal cancer after chemotherapy. Basic information, tumor stage and Autar score of deep vein thrombosis were collected in 160 patients with colorectal cancer. Logistic regression analysis was performed to explore the risk factors of thrombosis. This study was approved by the Ethics Committee of Fudan University Shanghai Cancer Center (number: 050432-4-2108*). Results: Compared with the control group, the R, TT and PLT of the group with thrombosis were decreased (P<0.05), while APTT, PT, DD and FDP were increased (P<0.05). The differences in various indicators between the group with thrombosis and the control group were statistically significant (P<0.05). Compared with the group without thrombosis, the K in the group with thrombosis decreased (P<0.05), while Angle, MA, CI, FIB, DD and FDP all increased (P<0.05). ROC curve analysis showed that in the assessment of hypercoagulable state in patients with colorectal cancer after chemotherapy, the area under curve (AUC) of TEG was 0.756, sensitivity was 67.5%, and specificity was 73.8%. The AUC of CCT was 0.691, sensitivity was 78.8%, and specificity was 56.2%. The combined detection AUC was 0.840, sensitivity was 80.0%, and specificity was 77.5%. In the analysis of risk factors, tumor stage, distant metastasis and Autar score were correlated with thrombus formation in patients with colorectal cancer after chemotherapy (P<0.05), and the differences of the three risk factors in K, Angle, MA, CI, Fib, DD and FDP were statistically significant (P<0.05). Conclusion: K, Angle, MA, CI, Fib, DD and FDP are the main indicators to reflect the hypercoagulable state, and the combined detection of TEG and CCT can better reflect the coagulation state of patients with colorectal cancer after chemotherapy. Tumor stage Ⅲ to Ⅳ, distant metastasis and high Autar score are risk factors for thrombosis. The incidence of thrombosis can be reduced by monitoring the relevant coagulation indicators in the high-risk population.

Key words: Colorectal cancer, Chemotherapy, Thromboelastography, Conventional coagulation test, Thrombosis

中图分类号: 

相关文章

[1] 刘志昱, 徐栋, 陈西昊, 李纪鹏. 局部进展期直肠癌新辅助放化疗后肿瘤退缩的影响因素分析及预测模型构建[J]. 中国癌症杂志, 2024, 34(2): 191-200.
[2] 上海市抗癌协会大肠癌专业委员会. 结直肠癌早筛、早诊、早治上海方案(2023年版)[J]. 中国癌症杂志, 2024, 34(1): 13-66.
[3] 张玲玲, 王湘漪, 魏星, 林莉, 汤传昊, 梁军. 止吐用低频电刺激仪防治非小细胞肺癌患者化疗导致恶心呕吐的回顾性研究[J]. 中国癌症杂志, 2023, 33(8): 776-781.
[4] 周聪, 何丽娜, 成小姣, 黄廷磊, 涂水平. RSPO3抑制体内结直肠癌移植瘤生长和增加NK细胞浸润的作用研究[J]. 中国癌症杂志, 2023, 33(7): 664-672.
[5] 冶俊玲, 郑小影, 郭新建, 陈瑞慧, 杨柳, 苟笑丹, 蒋汉梅. LncRNA SNHG5/miR-26a-5p/MTDH信号轴促进结直肠癌转移的机制研究[J]. 中国癌症杂志, 2023, 33(7): 673-685.
[6] 刘洋, 胡奕炀, 刘月平, 牛淑瑶, 丁平安, 田园, 郭洪海, 杨沛刚, 张泽, 郑涛, 檀碧波, 范立侨, 李勇, 赵群. 人工智能辅助技术在胃癌新辅助化疗患者HER2表达评估中的价值[J]. 中国癌症杂志, 2023, 33(4): 377-387.
[7] 董晓欢, 刘俊, 李洪选, 程妍, 李玥, 余雯, 蔡旭伟, 傅小龙. 食管癌新辅助放化疗中放疗累及野照射的初步研究[J]. 中国癌症杂志, 2023, 33(3): 267-273.
[8] 邵志博, 杨犇龙, 吴炅. 2022年中国乳腺癌重要临床试验成果及最新进展[J]. 中国癌症杂志, 2023, 33(2): 103-109.
[9] 蔡家洛, 朱锐秋, 李森, 曹亦军, 黄坊. 炎症癌相关成纤维细胞介导结直肠癌细胞耐药的机制研究[J]. 中国癌症杂志, 2023, 33(12): 1065-1072.
[10] 曾铖, 金奕滋, 李婷, 章真, 梁晓华, 唐曦, 刘天舒, 李琦, 沈赞, 姜斌, 王理伟, 张俊, 陈思宇, 周彩存, 高勇, 臧远胜, 李恒宇, 董宇超, 湛先保, 钟薏, 刘苓霜, 秦悦农, 胡夕春, 张剑. 上海市癌症患者化疗所致恶心呕吐的横断面研究[J]. 中国癌症杂志, 2023, 33(11): 1009-1017.
[11] 程纬浩, 王微丽, 毕钊, 张朝蓬, 孙晓, 赵家贤, 邱鹏飞, 陈鹏, 王永胜. COVID-19感染后手术时机与乳腺癌术后血栓并发症风险分析[J]. 中国癌症杂志, 2023, 33(10): 920-926.
[12] 胡可舒, 刘文凤, 张锋, 权冰, 殷欣. 长链非编码RNA LINC00601调控肝细胞癌奥沙利铂耐药的分子机制研究[J]. 中国癌症杂志, 2023, 33(1): 25-35.
[13] 张日虹, 郭宇, 梁贇, 陈洛海, 陈洁, 王玮. 辅助化疗对胃神经内分泌癌患者预后的意义[J]. 中国癌症杂志, 2022, 32(9): 807-817.
[14] 蒋金玲, 周尘飞, 奚文崎, 施敏, 耿梅, 赵丽琴, 蔡劬, 蒋劲松, 张俊. 5-FU节拍化疗策略优化及调节胃癌免疫微环境的体内实验研究[J]. 中国癌症杂志, 2022, 32(7): 596-605.
[15] 胡夕春, 胡志皇, 王碧芸, 王佳蕾, 陶荣, 张剑, 郭伟剑, 陈洁, 罗志国, 李婷, 黄明主, 邱立新, 桑友洲. 新型冠状病毒肺炎与抗肿瘤药物治疗[J]. 中国癌症杂志, 2022, 32(6): 499-511.